Stockscreener 앱 받기
9.22
3.46%
-0.33
시장 영업 전:
9.26
0.04
+0.43%
전일 마감가:
$9.55
열려 있는:
$9.53
하루 거래량:
492.35K
Relative Volume:
0.59
시가총액:
$379.10M
수익:
$128.29M
순이익/손실:
$-30.69M
주가수익비율:
-11.24
EPS:
-0.82
순현금흐름:
$-27.17M
1주 성능:
-4.55%
1개월 성능:
-15.65%
6개월 성능:
+15.68%
1년 성능:
-71.63%
1일 변동 폭
$9.19
$9.6085
1주일 범위
$9.19
$10.16
52주 변동 폭
$6.32
$34.71
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
RXST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
9.22 | 392.66M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-07-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-09 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 개시 | Piper Sandler | Neutral |
| 2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-10-29 | 개시 | Jefferies | Buy |
| 2024-08-20 | 재확인 | Needham | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-05-07 | 재확인 | BTIG Research | Buy |
| 2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 개시 | Morgan Stanley | Overweight |
| 2023-04-13 | 개시 | Oppenheimer | Outperform |
| 2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
RxSight down on CFO transition - MSN
Baillie Gifford & Co. Raises Stock Holdings in RxSight, Inc. $RXST - MarketBeat
RxSight, Inc. (NASDAQ:RXST) Given Consensus Rating of "Reduce" by Analysts - MarketBeat
Precision Trading with Rxsight Inc. (RXST) Risk Zones - Stock Traders Daily
RxSight (NASDAQ:RXST) Trading Down 0.9%Time to Sell? - MarketBeat
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - yourwyominglink.com
Decliners Report: Is RxSight Inc a potential multi bagger2025 Performance Recap & Risk Controlled Daily Trade Plans - baoquankhu1.vn
How Recent Developments Are Shaping The RxSight (RXST) Investment Story - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - ACCESS Newswire
Expert Outlook: RxSight Through The Eyes Of 5 Analysts - Benzinga
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight (RXST) soars 14.1%: Is further upside left in the stock? - MSN
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight stock price target raised to $11.50 from $11.00 at Jefferies By Investing.com - Investing.com South Africa
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com
RxSight Up 11% on Preliminary Q4, Full Year Results - ocbj.com
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference By Investing.com - Investing.com South Africa
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference - Investing.com Nigeria
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
RxSight (RXST) Reiterated at Neutral by UBS: 'Need More Regular Signs of Come-back' - StreetInsider
RxSight (RXST) Reiterated at Hold by Stifel Amid LAL, LDD Slowdown - StreetInsider
Benign Growth For RxSight, Inc. (NASDAQ:RXST) Underpins Stock's 30% Plummet - 富途牛牛
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
RxSight guides FY revenue above previous estimates, names new CFO - MSN
RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO - Nasdaq
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance - Investing.com
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer - manilatimes.net
RxSight, Inc. Reports Preliminary Financial Results for Q4 and Full-Year 2025; Announces Appointment of New CFO - Quiver Quantitative
RxSight says Mark Wilterding appointed as CFO effective Jan 11, 2026 - marketscreener.com
RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026 - TradingView — Track All Markets
RXSTRxsight, Inc. Latest Stock News & Market Updates - Stock Titan
RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026 - marketscreener.com
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely - Sahm
RxSight, Inc. (RXST) Investor Outlook: A Close Look At Its 7.98% Potential Upside - DirectorsTalk Interviews
Is RxSight Inc. stock dividend yield sustainableJuly 2025 Institutional & Stepwise Entry/Exit Trade Alerts - Улправда
Is RxSight Inc. stock trading at a premium valuation2025 Fundamental Recap & Real-Time Buy Signal Alerts - Улправда
Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - marketscreener.com
Will RxSight Inc. stock outperform international peers2026 world cup usa national team group stage playmakers possession football tactical prediction tactical review - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ... - bdtonline.com
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
0.96%
자본화:
|
볼륨(24시간):